SWX:NOVNPharmaceuticals
Is It Too Late To Consider Novartis (SWX:NOVN) After A 30% One-Year Jump?
Some investors may be wondering whether Novartis at around CHF116 per share is still good value, or if most of the opportunity is already reflected in the price.
The stock has had a 1% decline over the past week and past month, while posting returns of 7.2% year to date and 30.2% over the last year. This may catch the eye of investors weighing reward against risk.
Recent headlines have highlighted Novartis as a large, established player in global pharmaceuticals. This keeps it on the radar...